59
Participants
Start Date
January 13, 2021
Primary Completion Date
October 25, 2023
Study Completion Date
August 7, 2028
CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
JWCAR029 will be administered at dose level: 1 x 10\^8 CAR+T cells
Peking University Cancer Hospital, Beijing
Peking University Third Hospital, Beijing
Fujian Medical University Consonancy Hospital, Fuzhou
Guangdong Province people hospital, Guanzhou
Henan Province Cancer Hospital, Zhengzhou
Jiangsu Province People Hospital, Nanjing
Fudan University Shanghai Cancer Center, Shanghai
Zhongshan Hospital affiliated to Fudan University, Shanghai
Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin
Tianjin Cancer Hospital, Tianjin
The First Affiliated Hospital of Zhejiang University, Hangzhou
Zhejiang province Cancer Hospital, Hangzhou
Shanghai Ming Ju Biotechnology Co., Ltd.
INDUSTRY